Key Details
Last Dividend
$0.78Annual ROE
37.29%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
May 03, 2023Recent annual earnings:
Feb 21, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
Aug 31, 2022Next split:
N/ARecent split:
Mar 31, 2023Analyst ratings
Recent major analysts updates
Screeners with STAR included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Similar stocks
The vacation brand's art program will spotlight up-and-coming Caribbean artists on Star of the Seas MIAMI , Jan. 16, 2025 /PRNewswire/ -- More ways to bring to life the heart of the Caribbean, its people, beauty and culture are on deck. Royal Caribbean announced that its " Artist Discovery Program " returns to the Caribbean, calling on brilliant artists across the region to showcase their work on the next combination of the best of every vacation, Star of the Seas.
BOSTON , Jan. 13, 2025 /PRNewswire/ -- The Board of Directors of Liberty All-Star Growth Fund, Inc. (NYSE: ASG) has declared a distribution of $0.12 per share payable on March 10, 2025 to shareholders of record on January 24, 2025. This distribution is in accordance with the Fund's current distribution policy of paying distributions on its shares totaling approximately 8 percent of its net asset value per year, payable in four quarterly installments of 2 percent.
Astria Therapeutics, Inc.'s STAR-0215 shows 90-96% reduction in HAE attack frequency, with a twice-a-year dosing regimen, positioning it as a transformative therapy. The company has a strong cash balance of $344 million, ensuring a runway until 2027, supporting continued development and trials. Competitive positioning is strong, with STAR-0215 outperforming existing treatments like Takhzyro and Haegarda in both efficacy and dosing convenience.
The new lab will leverage PacBio's HiFi sequencing technology to broaden access to highly accurate long-read sequencing and multi-omics solutions in Southeast Asia The new lab will leverage PacBio's HiFi sequencing technology to broaden access to highly accurate long-read sequencing and multi-omics solutions in Southeast Asia
PLANO, Texas , Sept. 19, 2024 /PRNewswire/ -- Venezuelan singer and songwriter Danny Ocean has launched his highly anticipated "Reflexa" tour across the United States and Canada, electrifying audiences with his signature energy.
Starting August 2025, the next combination of every vacation will headline Port Canaveral (Orlando), Florida, with the record-setting lineup of Icon Class experiences MIAMI , Aug. 20, 2024 /PRNewswire/ -- Royal Caribbean International's Star of the Seas will soon double the world's best vacation count in one of the world's top travel destinations, and the full lineup of unrivaled experiences in store has been revealed. From thrills like the fastest and tallest waterslides to 40-plus ways to dine and drink combined with adventures in idyllic destinations like the cruise line's Perfect Day at CocoCay in The Bahamas, the next combination of the best of every vacation sets the stage for everyone to make memories from Port Canaveral (Orlando), Florida.
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients - Dermata continues discussions with potential botulinum toxin partners for DMT410 - Raised $2.3 million in net proceeds from financing completed in 2Q 2024 SAN DIEGO, CA / ACCESSWIRE / August 7, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW)("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today highlighted recent corporate progress and reported financial results for the second quarter ended June 30, 2024. "We are excited to have enrolled over 50% of patients in our DMT310 Phase 3 STAR-1 trial, and we look forward to the second half of 2024 as our team continues to work diligently to complete enrollment of the DMT310 STAR-1 trial," commented Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer.
LAS VEGAS, NV / ACCESSWIRE / July 24, 2024 / Star Alliance International Corp. (OTC PINK:STAL), ("STAR or the Company"). STAR is pleased to confirm that HRaspirin is testing its new and exciting HRADocs program that offers electronic signatures plus a document management system.
The newest cocktail-inspired RTD offering from America's favorite rum brand launches a nationwide sweepstakes that goes all-in on summer adventures and bold flavor NEW YORK , July 22, 2024 /PRNewswire/ -- Summer bucket lists are back, and there's one item that's topping lists nationwide
The homebuilder was also recognized for its philanthropic efforts and commitment to sustainability The homebuilder was also recognized for its philanthropic efforts and commitment to sustainability
FAQ
- What is the primary business of iStar?
- What is the ticker symbol for iStar?
- Does iStar pay dividends?
- What sector is iStar in?
- What industry is iStar in?
- What country is iStar based in?
- When did iStar go public?
- Is iStar in the S&P 500?
- Is iStar in the NASDAQ 100?
- Is iStar in the Dow Jones?
- When was iStar's last earnings report?
- When does iStar report earnings?
- Should I buy iStar stock now?